The UK's Competition and Markets Authority (" CMA ") has fined three pharmaceutical companies a combined £50 million following an investigation into certain "pay-for-delay" patent settlement agreements. On 12 February 2016, the CMA published a press release confirming its preliminary decision that the agreements between Glaxosmithkline ( GSK ) and two generic companies had the object or effect of restricting, distorting or preventing competition. The payments made by GSK to each of the other parties in exchange for delayed entry also amounted to an abuse of GSK's dominant market position. GSK held a number of patents protecting paroxetine, a drug used for the treatment of depression and anxiety disorders. These patents had allowed GSK's Seroxat product to gain blockbuster status. The generic companies sought to enter the UK market with a generic version of paroxetine, and GSK had commenced proceedings against both generic companies alleging that such entry would infringe GSK's patents.